Puma Biotechnology to Host Q2 2025 Earnings Call and Discuss Progress in Cancer Treatment Innovations

Puma Biotechnology will host a conference call on August 7, 2025, to discuss Q2 2025 financial results. The company focuses on cancer care innovation with products like NERLYNX and ongoing alisertib trials. Market cap is $171.75 million with significant institutional ownership at 59.27%.

Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company focused on cancer care innovation, will host a conference call on August 7, 2025, at 1:30 p.m. PT/4:30 p.m. ET to discuss its second quarter 2025 financial results. The call can be accessed by dialing 1-877-709-8150 (domestic) or 1-201-689-8354 (international). A live webcast and presentation slides will be available on the company's website [1].

Puma Biotechnology's portfolio includes NERLYNX® (neratinib), an oral medication approved for the extended adjuvant treatment of early-stage HER2-overexpressed/amplified breast cancer and advanced/metastatic HER2-positive breast cancer. The company also has ongoing trials for alisertib, a selective small molecule inhibitor of aurora kinase A, with Phase II clinical trials for small cell lung cancer (ALISCA™-Lung1) and HER2-negative, HR-positive metastatic breast cancer (ALISCA™-Breast1) [1].

As of the latest available data, Puma Biotechnology has a market capitalization of $171.75 million, with significant institutional ownership at 59.27% [1]. The company's focus on innovative cancer care solutions and its pipeline of products make it a notable player in the biopharmaceutical industry.

References:
[1] https://www.morningstar.com/news/business-wire/20250724963277/puma-biotechnology-to-host-conference-call-to-discuss-second-quarter-2025-financial-results